2024
Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in Uganda
Amutuhaire W, Semitala F, Kimera I, Namugenyi C, Mulindwa F, Ssenyonjo R, Katwesigye R, Mugabe F, Mutungi G, Ssinabulya I, Schwartz J, Katahoire A, Musoke L, Yendewa G, Longenecker C, Muddu M. Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in Uganda. Journal Of Human Hypertension 2024, 38: 452-459. PMID: 38302611, PMCID: PMC11076202, DOI: 10.1038/s41371-024-00897-3.Peer-Reviewed Original ResearchBP controlDuo-therapyAmlodipine 5Blood pressureWorld Health OrganizationMono-therapyCox proportional hazards analysisUrban HIV clinicCox proportional hazards modelsProportional hazards analysisBlood pressure controlAnti-hypertensive treatmentStage I hypertensionHIV care settingsProportional hazards modelHypertensive PLHIVMonotherapy groupPill burdenHIV clinicCohort studySystolic BPHazards modelPressure controlPatientsMmHg
2022
Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism
Sadeghipour P, Jenab Y, Moosavi J, Hosseini K, Mohebbi B, Hosseinsabet A, Chatterjee S, Pouraliakbar H, Shirani S, Shishehbor MH, Alizadehasl A, Farrashi M, Rezvani MA, Rafiee F, Jalali A, Rashedi S, Shafe O, Giri J, Monreal M, Jimenez D, Lang I, Maleki M, Goldhaber SZ, Krumholz HM, Piazza G, Bikdeli B. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism. JAMA Cardiology 2022, 7: 1189-1197. PMID: 36260302, PMCID: PMC9582964, DOI: 10.1001/jamacardio.2022.3591.Peer-Reviewed Original ResearchConceptsConventional catheter-directed thrombolysisRV/LV ratioRisk pulmonary embolismCatheter-directed thrombolysisProportion of patientsPulmonary embolismLV ratioMajor bleedingPrimary outcomeRight ventricleClinical trialsIntermediate-high risk pulmonary embolismDefinitive clinical outcome trialsMain safety outcomeMajor gastrointestinal bleedingRV/LVClinical events committeeClinical outcome trialsLarge cardiovascular centresCause mortalityEfficacy outcomesGastrointestinal bleedingMonotherapy groupOutcome trialsSecondary outcomesOlutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Watts J, Baer M, Yang J, Prebet T, Lee S, Schiller G, Dinner S, Pigneux A, Montesinos P, Wang E, Seiter K, Wei A, De Botton S, Arnan M, Donnellan W, Schwarer A, Récher C, Jonas B, Ferrell P, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard S, Brevard J, Henrick P, Mohamed H, Cortes J. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. The Lancet Haematology 2022, 10: e46-e58. PMID: 36370742, DOI: 10.1016/s2352-3026(22)00292-7.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaInhibitor of mutant isocitrate dehydrogenase 1Recommended phase 2 doseIDH1-mutated acute myeloid leukemiaPhase 2 doseDose-limiting toxicityCombination therapy groupMyeloid leukemiaCombination therapyMyelodysplastic syndromeClinical activityFebrile neutropeniaMonotherapy groupSmall-molecule inhibitor of mutant isocitrate dehydrogenase 1Eastern Cooperative Oncology Group performance status 0Treatment-emergent adverse eventsHigh-risk myelodysplastic syndromeRefractory acute myeloid leukemiaOpen-label clinical trialTherapy groupDose-escalation cohortsPerformance status 0Phase 1/2 studyTreatment-naive patientsPhase 1/2 trial
2020
Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Kamp W, Park H, Slovak R, Ludwig J, Kang I, Kim H. Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Journal Of Clinical Oncology 2020, 38: 160-160. DOI: 10.1200/jco.2020.38.4_suppl.160.Peer-Reviewed Original ResearchDual immune checkpoint blockadeAnti-PD-1 antibodyColorectal cancerPD-1T cellsImmune responseMurine colorectal cancer cellsBALB/c miceDual checkpoint inhibitionExpression of TIM3Subcutaneous flank injectionNumber of CD8PD-1 inhibitionImmune checkpoint blockadeDeficient mismatch repairColorectal cancer cellsHigh microsatellite instabilitySignificant clinical impactPotential escape mechanismsCombination immunotherapyImmunosuppressive checkpointsCheckpoint inhibitorsMonotherapy groupCheckpoint blockadeMost patientsThe radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
Lundsten S, Spiegelberg D, Raval NR, Nestor M. The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 980-990. PMID: 31912256, PMCID: PMC7075859, DOI: 10.1007/s00259-019-04673-1.Peer-Reviewed Original ResearchConceptsComplete remissionToxicity profileNeuroendocrine tumorsSomatostatin receptorsCombination treatmentHistological analysisFavorable toxicity profileBetter therapeutic resultsDose-limiting organHeat shock protein 90 inhibitorShock protein 90 inhibitorsNeuroendocrine tumor xenograftsMonotherapy groupGlomerular injuryUnwanted side effectsCombination groupTherapeutic resultsTherapeutic effectTumor xenograftsSide effectsTumor uptakeRemissionXenograftsTumorsHSP70 upregulation
2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology 2016, 17: 1590-1598. PMID: 27733243, PMCID: PMC5648054, DOI: 10.1016/s1470-2045(16)30496-x.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaTreatment-related adverse eventsAdvanced urothelial carcinomaSerious adverse eventsPlatinum-based chemotherapyUrothelial carcinomaAdverse eventsNivolumab monotherapyObjective responseInvestigator-assessed objective responsePrevious platinum-based chemotherapyProtocol-defined reasonsSafety of nivolumabManageable safety profileOpen-label studyPD-L1 expressionDurable clinical responsesDose of treatmentBristol-Myers SquibbCheckMate 032Data cutoffElevated lipaseMonotherapy groupPrimary endpointStudy drug
2013
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. New England Journal Of Medicine 2013, 369: 1892-1903. PMID: 24206457, DOI: 10.1056/nejmoa1303154.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseGlomerular filtration rateAngiotensin receptor blockersAcute kidney injuryCombination therapyEnd pointKidney injuryDiabetic nephropathyPrimary end-point eventAngiotensin-converting enzyme inhibitorPrimary end pointSecondary end pointsCombination therapy groupRenal end pointsRisk of hyperkalemiaEnd-point eventsType 2 diabetesBody surface areaConclusion Combination therapyAngiotensin inhibitionCardiovascular eventsMonotherapy groupAdverse eventsCreatinine ratioRenal disease
2012
A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
Gottlieb A, Langley R, Strober B, Papp K, Klekotka P, Creamer K, Thompson E, Hooper M, Kricorian G. A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. British Journal Of Dermatology 2012, 167: 649-657. PMID: 22533447, PMCID: PMC3504074, DOI: 10.1111/j.1365-2133.2012.11015.x.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisCombination therapyAdverse eventsWeek 24Etanercept monotherapyMonotherapy groupPlaque psoriasisWeek 12Necrosis factor inhibitor therapyStatic Physician's Global AssessmentGlobal assessmentMethotrexate combination therapyPhysician global assessmentPlacebo-controlled studySerious adverse eventsCombination therapy groupProportion of patientsAddition of methotrexatePASI 50PASI 75PASI 90Primary endpointSevere psoriasisAcceptable tolerabilityPsoriasis Area
2007
FK778 in Experimental Xenotransplantation: A Detailed Analysis of Drug Efficacy
Schrepfer S, Deuse T, Koch-Nolte F, Krieger T, Haddad M, Schäfer H, Pelletier M, Robbins R, Reichenspurner H. FK778 in Experimental Xenotransplantation: A Detailed Analysis of Drug Efficacy. The Journal Of Heart And Lung Transplantation 2007, 26: 70-77. PMID: 17234520, DOI: 10.1016/j.healun.2006.10.013.Peer-Reviewed Original ResearchMeSH KeywordsAlkynesAnimalsAntibodies, Anti-IdiotypicAorta, AbdominalCricetinaeDisease Models, AnimalEndothelium, VascularFlow CytometryGraft RejectionHumansImmunoglobulin GImmunoglobulin MInterleukin-2 Receptor alpha SubunitIsoxazolesMaleNitrilesRatsRats, Inbred BNRats, Inbred LewT-LymphocytesTransplantation, HeterologousTreatment OutcomeConceptsXenograft rejectionCombination regimensHyperacute rejectionMyocyte necrosisAnalysis of drug efficacyEfficacy of FK778Model of hyperacute rejectionXenoantibody productionMonotherapy groupImmunosuppressive treatmentCD25 expressionFK778TacrolimusUntreated ratsXenotransplantation modelAortic xenograftsDose-dependentlyComplement depositionExperimental xenotransplantationSirolimusHumoral responseDrug efficacyXenograft infiltrationXenoreactive IgMRegimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply